Transforming oncology with a pan-European approach to data sharingBetween genomic data, electronic health records and digital health tools, we have all the information we need to Share XTransforming oncology with a pan-European approach to data sharinghttps://pharmaphorum.com/views-analysis-oncology/transforming-oncology-with-a-pan-european-approach-to-data-sharing/
The Japanese healthcare revolutionSomething that always strikes me when visiting Japan is the uber-modern infrastructure and services enjoyed by residents and Share XThe Japanese healthcare revolutionhttps://pharmaphorum.com/views-analysis-oncology/the-japanese-healthcare-revolution/
The promise and pitfalls of molecular testing in oncologyGreat strides have been made in the diagnosis and treatment of cancer. However, a variety of challenges remain Share XThe promise and pitfalls of molecular testing in oncologyhttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/research-partnership-molecular-testing-cancer/
Smarter thinking about pharmaceutical marketingRobb DeFilippis, from end-to-end global creative production and sourcing partner Tag, discusses how a more effective multichannel pharma Share XSmarter thinking about pharmaceutical marketinghttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/tag-pharmaceutical-marketing-production/
NICE’s track record in cancer drugs: the impact of the CDF and interim fundingLeela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0 Share XNICE’s track record in cancer drugs: the impact of the CDF and interim fundinghttps://pharmaphorum.com/views-and-analysis/nices-track-record-in-cancer-drugs-the-impact-of-the-cdf-and-interim-funding/
Getting patients round the virtual tableIf pharma wants to be truly patient-centric, it needs to be talking to patients. This may seem obvious, Share XGetting patients round the virtual tablehttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/impetus-digital-patient-centric-engagement/
Revealing the true value of new cancer drugs to payersMarc Botteman and Ben van Hout from Pharmerit International discuss how to navigate the value challenges of new Share XRevealing the true value of new cancer drugs to payershttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/pharmerit-cancer-drug-value-payers/
AstraZeneca and lung cancer: the pharmaphorum podcastThis episode of the pharmaphorum podcast focuses on lung cancer, with AstraZeneca’s VP, global franchise head, Tagrisso TDR Share XAstraZeneca and lung cancer: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/astrazeneca-and-lung-cancer
Adapting for the future of oncology trialsAdvanced analytical solutions provider Cytel is at the forefront of rapid changes in oncology R&D. We spoke with Share XAdapting for the future of oncology trialshttps://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/cytel-future-adaptive-trials-cancer/
